Carbapenem-resistant Enterobacterales: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
* First-line includes [[meropenem-vaborbactam]] or [[ceftazidime-avibactam]], directed by susceptibility results[[CiteRef:paul2022eu]] |
* First-line includes [[meropenem-vaborbactam]] or [[ceftazidime-avibactam]], directed by susceptibility results[[CiteRef:paul2022eu]] |
||
* For metallo-β-lactamases or extensively resistant bacteria, consider [[cefiderocol]] or [[aztreonam]] plus [[ceftazidime-avibactam]] |
* For metallo-β-lactamases or extensively resistant bacteria, consider [[cefiderocol]] or [[aztreonam]] 2 g IV q8h plus [[ceftazidime-avibactam]] 2.5 g IV q8h (both run concurrently over 3 hours) |
||
* For non-severe infections, consider [[aminoglycosides]], including [[plazomicin]]; [[tigecycline]] would be second-line, though it can be considered in pneumonia |
* For non-severe infections, consider [[aminoglycosides]], including [[plazomicin]]; [[tigecycline]] would be second-line, though it can be considered in pneumonia |
||
Revision as of 17:00, 22 November 2025
Management
- First-line includes meropenem-vaborbactam or ceftazidime-avibactam, directed by susceptibility resultsCiteRef:paul2022eu
- For metallo-β-lactamases or extensively resistant bacteria, consider cefiderocol or aztreonam 2 g IV q8h plus ceftazidime-avibactam 2.5 g IV q8h (both run concurrently over 3 hours)
- For non-severe infections, consider aminoglycosides, including plazomicin; tigecycline would be second-line, though it can be considered in pneumonia
